Racial differences in compliance with NCEP-II recommendations for secondary prevention at a veterans affairs medical center

Ethnicity and Disease

Volumn 12, Issue 1, 2002, Pages

  Williams, Marcus L ^a   Morris II, Michael T ^a   Ahmad, Umad ^a   Yousseff, Manal ^a   Li, Win ^a   Ertel, Norman ^a  

^a VANJHCS   (United States)

Author keywords

Coronary disease; Lipids; NCEP II; Outcomes; Risk factors; Secondary prevention

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; EDUCATION PROGRAM; HUMAN; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PREVALENCE; PUBLIC HOSPITAL; RACE DIFFERENCE; SECONDARY PREVENTION; SMOKING; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; EVALUATION STUDIES; FEMALE; GUIDELINE ADHERENCE; HOSPITALS, VETERANS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINES; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN; UNITED STATES;

EID: 0036248302     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TesCAPS
7. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
8. Serum cholesterol levels among persons 20 years of age and over, according to sex, age, race, and Hispanic origin: United States, 1960-62, 1971-74, 1976-80, and 1988-94
9. The lipid treatment assessment project (L-TAP)
10. Mortality differences between Black and White men in the USA: Contribution of income and other risk factors among men screened for the MRFIT
11. Coronary heart disease incidence and survival in African-American women and men. The NHANES I epidemiologic follow-up study
12. Racial variation in cardiac procedure use and survival following acute myocardial infarction in the department of veterans affairs
13. Population awareness and control of hypertension and hypercholesterolemia
14. Medical apatheid: An American perspective
15. The role of genetic and environmental factors in cardiovascular disease in African Americans
16. Cholesterol lowering in the elderly: Results of the cholesterol reduction in seniors program (CRISP) pilot study
17. The low-density lipoprotein cholesterol-lowering effect of pravastatin and factors associated with achieving targeted low-density lipoprotein levels in an African-American population
18. Efficacy and tolerability of lovastatin in 459 African Americans with hypercholesterolemia
19. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
20. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system
21. Inadequate treatment with HMG-CoA Reductase Inhibitor by health care providers
22. Primary care practice adherence to National Education Program Guidelines for patients with coronary heart disease
23. Racial differences in high-density lipoprotein and coronary heart disease incidence in the usual-care group of the Multiple Risk Factor Intervention Trial